ICIs include programmed cell death protein 1 (PD‐1), programmed death ligand 1 (PD‐L1), and cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4) inhibitors, and have revolutionized the NSCLC treatment landscape.9 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.